Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.77 |
| ▸ | CCR2 | P41597 | 6/20 | 0.77 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640525 | 0.94 | ROCK2 (0.68) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5640516 | 0.94 | ROCK2 (0.68) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5641841 | 0.88 | ROCK2 (0.78) | ROCK2ROCK1CCR2KCNH2 | |
| SCHEMBL5639760 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5639733 | 0.84 | ROCK2 (0.81) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5639880 | 0.82 | ROCK2 (0.82) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL12192853 | 0.82 | ROCK1 (0.59) | ROCK2ROCK1CCR2CCR3HRH1 | |
| SCHEMBL5640347 | 0.81 | ROCK2 (0.80) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5637873 | 0.81 | ROCK1 (0.88) | ROCK2ROCK1CCR2KCNH2 | |
| SCHEMBL5637871 | 0.81 | ROCK1 (0.88) | ROCK2ROCK1CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.